Help improve the information
Suggest a correction, missing detail, or peptide addition by .
FDA-approved drug context
This entry has documented FDA-approved drug context, so any reported use details on this page should be read as labeled guidance and followed only with clinician oversight.
Overview
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes management (as Ozempic) and chronic weight management (as Wegovy). With over 17,000 participants in clinical trials, it demonstrates significant weight loss potential (average 15-20% body weight reduction) through appetite suppression, slowed gastric emptying (how quickly food leaves the stomach), and enhanced glucose control.
Reported benefits
- FDA-approved GLP-1 agonist for type 2 diabetes and chronic weight management.
- Demonstrates significant weight loss (15-20% average), improved glycemic control, cardiovascular benefits, and convenient dosing options in both injectable and oral formulations.
- ~15–17% body weight loss
- HbA1c reduction
- Cardiovascular benefit (proven)
- Weekly injectable or daily oral dosing
- Appetite suppression
- Reduced cardiovascular events
Mechanism of action
Semaglutide activates GLP-1 receptors in the hypothalamus (a brain region involved in appetite, stress, and hormone control) (appetite suppression), pancreas (insulin secretion, glucagon suppression), and gut (gastric emptying (how quickly food leaves the stomach) delay). C18 fatty acid acylation enables albumin binding, extending half-life (how long it stays active) to ~7 days.
It also has direct cardiac and vascular protective effects.
Reported Use
FDA-labeled guidance
This entry has documented FDA-approved drug context. Reported dose and timing details below should be read as labeled medical guidance and followed only with clinician oversight.
Typical dose
Start 0.25mg weekly, titrate monthly to target dose
Frequency
Weekly (injectable); daily (oral)
Injection sites
Abdomen, thigh, or upper arm (rotate weekly)
Best timing
Same day each week (injectable); morning empty stomach (oral)
Effects timeline
Appetite: 1-2 weeks, Weight loss: 4-8 weeks, Full effects: 3-4 months
Storage
Refrigerate before first use, then refrigerate or room temp up to 28 days
Cycle length
Ongoing as prescribed by healthcare provider
Break between
Not applicable - continuous therapy
Loading viewer
Preparing 3D peptide scene
Quick Signals
At A Glance
A faster read on evidence, focus, structure, and status.
Evidence
Established clinical use
This peptide has an FDA-approved drug context and a strong indexed research footprint.
4,354 indexed studiesCurrent level
Established use
Scale: low evidence to established use
Safety
Side Effects And Safety
Switch between common side-effect notes and stop criteria to keep safety context visible.
Reported or plausible side effects
- Most common side effects are gastrointestinal (nausea, vomiting, diarrhea)
Key cautions
- FDA-approved medication - use under medical supervision
- Start with low dose and titrate slowly to minimize side effects
- Contraindicated in personal/family history of medullary thyroid cancer
- Not recommended during pregnancy or breastfeeding
- Regular monitoring recommended for optimal results and safety
Molecule
Molecular Information
Core structure fields that help explain what kind of peptide this is and how much sequence detail is available.
Molecular weight
4,113.64 Da
Chain length
31 amino acids
Sequence type
Acylated GLP-1 analogue
Derived from
Novo Nordisk
Amino acid sequence source string
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Acylated with C18 fatty diacid via γ-Glu spacer for extended half-life
Context
Important Context
The main context that changes how confidently this peptide should be interpreted.
Research status
Established clinical use. FDA-approved for T2D and obesity. Extensive Phase III data (SUSTAIN, STEP, SELECT programs). Published in NEJM, Lancet. Proven cardiovascular benefit.
Regulatory and sport status
FDA review shows FDA-approved drug context. confirmed by openFDA and current FDA labeling. Sport review: Monitored, not prohibited in the current WADA Monitoring Program.
Route Notes
Route-Specific Notes
Only shown when the source material adds route-specific details beyond the quick-start guide.
Injectable
- Administration: Use the exact labeled pen product and follow the product-specific instructions for dose escalation and missed doses.
- Absorption: Product-specific injectable absorption is not summarized here as a generic PK claim.
- Cycle: Ongoing therapy while clinically indicated, not a peptide cycle.
- Additional: Injectable semaglutide guidance differs by product, indication, and pen strength.
- Availability: Not applicable.
Oral
- Administration: Take the oral formulation exactly as labeled on an empty stomach with limited water and the required wait before food, drink, or other medications.
- Absorption: Absorption depends heavily on empty-stomach administration and label-specific timing.
- Cycle: Ongoing therapy while clinically indicated, not a peptide cycle.
- Additional: The oral product has route-specific absorption constraints that do not apply to the injectable pens.
- Availability: Not applicable.
Compare
How Well Documented Is It?
A quick five-point snapshot of how visible and well-documented this peptide is. Higher values mean more coverage or clearer status in that area, not better medical performance.
Research
How much published research coverage this peptide has in the linked sources, with an approval-context floor for clearly established drug products.
Source: PubMed
Regulatory
How clearly the approval or regulatory status is documented for this entry.
Source: openFDA drugsfda API
Sport
How clearly sports or competition status is documented in the linked review sources.
Source: WADA Monitoring Program
Breadth
How broadly this peptide appears across discussion topics and use-case groupings in the catalog.
Source: Curated site taxonomy
Sequence
How much structure or residue-sequence detail is available for this entry.
Source: Catalog seed
Protocols
Research Protocols
Common protocol-style rows shown in a consistent table layout so every peptide page is easy to compare.
| Goal | Dose | Route | Frequency |
|---|---|---|---|
| Weight loss | Up to 2.4 mg | SubQ | 1x weekly |
| T2D | Up to 1 mg | SubQ | 1x weekly |
Research
What It Has Been Studied For
Plain-language summaries of the main health areas where this peptide shows up in the linked research.
Stacking
What People Commonly Stack It With
A plain-language view of compounds that are commonly discussed alongside this peptide in the source material.
Practical
Preparation, Quality, And Expectations
Operational checklist blocks designed for quick scanning and repeatable page structure.
How to reconstitute
- •Use only FDA-approved products from licensed pharmacies
- •Follow specific product instructions for your prescribed formulation
- •Injectable: Prime pen if first use, select dose, inject subcutaneously
- •Oral: Take on empty stomach with minimal water, wait 30 minutes
- •Rotate injection sites if using injectable form
- •Store according to product-specific requirements
- •Pre-filled pen (pharmaceutical).
- •No reconstitution needed.
Quality indicators
Good signs
- FDA-Approved Products Only
- Proper Storage Maintained
- Pharmaceutical from pharmacy/prescription.
Avoid
- Avoid Compounded Versions
- Online Non-Pharmacy Sources
- Compounded semaglutide varies in quality
- FDA has issued warnings about non-pharmaceutical versions.
What to expect
Appetite suppression; possible nausea.
5–10% weight loss.
12–17% weight loss at target dose.
Weight maintenance requires continued use.
References
Research And Source List
Structured reference cards with source metadata and a direct link so users can inspect the original study/source.
openFDA drugsfda API
FDA database | 2026 access
Current U.S. approval-database record for semaglutide products.
Wegovy label
FDA label | 2024
Product-specific dosing, warnings, adverse reactions, and storage guidance for semaglutide.
WADA Monitoring Program
WADA | 2026
Current anti-doping monitoring source showing semaglutide is monitored rather than prohibited.
Catalog profile
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes management (as Ozempic) and chronic weight management (as Wegovy). With over 17,000 participants in clinical trials, it demonstrates significant weight loss potential (average 15-20% body weight reduction) through appetite suppression, slowed gastric emptying, and enhanced glucose control.
PubMed search
Direct PubMed search for indexed publications that mention Semaglutide.